To ensure that a patient’s test is billed to their 2024 health benefits, testing must be started before the end of the year. For exome, genome, or Xpanded testing, if you do not expect parental samples to be received before the end of the year, please contact us at support@genedx.com to determine how to proceed.
The diagnostic rate is highest when a trio is submitted and analyzed, as the inclusion of parental data improves the ability to classify variants. The absence of parental data may lead to higher rates of variants of unknown significance that could otherwise be dismissed based on inheritance patterns.
